Reply to "Tolerogenic insulin peptide therapy precipitates type 1 diabetes"

Daniel C, Weigmann B, Von Boehmer H (2017)

Publication Type: Journal article, Letter

Publication year: 2017

Journal

Journal of Experimental Medicine Rockefeller University Press

Book Volume: 214

Pages Range: 2157-2159

Journal Issue: 7

DOI: 10.1084/jem.20170285

Abstract

In this issue of JEM, Bergman et al. (https://doi.org/10.1084/jem.20160471) challenge the data published in our previous JEM paper on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Here, we provide a response to these data and suggest that appropriate subimmunogenic conditions are required to induce Foxp3+ regulatory T cell conversion.

Authors with CRIS profile

Benno Weigmann Medizinische Fakultät

Involved external institutions

Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (HMGU) / Helmholtz Munich

Germany (DE) Harvard University

United States (USA) (US)

How to cite

APA:

Daniel, C., Weigmann, B., & Von Boehmer, H. (2017). Reply to "Tolerogenic insulin peptide therapy precipitates type 1 diabetes". Journal of Experimental Medicine, 214(7), 2157-2159. https://doi.org/10.1084/jem.20170285

MLA:

Daniel, Carolin, Benno Weigmann, and Harald Von Boehmer. "Reply to "Tolerogenic insulin peptide therapy precipitates type 1 diabetes"." Journal of Experimental Medicine 214.7 (2017): 2157-2159.

BibTeX: Download